.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Citi
Accenture
Teva
Cipla
US Department of Justice
Merck
Chinese Patent Office
Johnson and Johnson
Chubb

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,878,703

« Back to Dashboard

Summary for Patent: 6,878,703

Title: Pharmaceutical composition
Abstract:A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: ##STR1## The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
Inventor(s): Sada; Toshio (Tokyo, JP), Mizuno; Makoto (Funabashi, JP)
Assignee: Sankyo Company, Limited (Tokyo, JP)
Application Number:10/442,874
Patent Claim Types:
see list of patent claims
Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,878,703

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-354327Nov 21, 2000
Japan2001-164009May 31, 2001

International Patent Family for Patent: 6,878,703

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway332938► Subscribe
South Korea100656716► Subscribe
MexicoPA03004463► Subscribe
Norway20032261► Subscribe
South Korea20030096235► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Argus Health
Novartis
Medtronic
Cantor Fitzgerald
Baxter
AstraZeneca
Cerilliant
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot